Allergan
Skip to content Global Locations- Contact Us- Search- About Us- History Leadership Global Locations What We Treat- Eye Care: Dry Eye Glaucoma Other Eye Conditions Neurosciences: Blepharospasm Cervical Dystonia Strabismus Obesity Intervention Medical Aesthetics: Breast Aesthetics Facial Aesthetics Medical Dermatology: Acne Psoriasis Severe Primary Axillary Hyperhidrosis Other Skin...
author: PINT [ www.pint.com ]
Drug Approvals - B
- ANDA 76-476 2/11/04 2/12/04 - - Benazepril Hydrochloride Tablets, 5, 10, 20 & 40 mg, Rx Andrx Pharmaceuticals ANDA 76-267 2/11/04 2/12/04 - - Benazepril Hydrochloride Tablets, 5, 10, 20 & 40 mg, Rx Tentatively Approved Andrx Pharmaceuticals ANDA 76-267 2/26/03 - - - Benazepril Hydrochloride Tablets, 5, 10, 20 & 40 mg, Rx Teva Pharmaceuticals ANDA 76-211 2/11/04 2...
http://www.fda.gov/cder/orange/appendix_a.txt
3, ACETAMINOPHEN ACETAMINOPHEN W/ CODEINE PHOSPHATE #3, ACETAMINOPHEN ACETAMINOPHEN W/ CODEINE PHOSPHATE, ACETAMINOPHEN ACETAMINOPHEN W/ CODEINE, ACETAMINOPHEN ACETAMINOPHEN, ACETAMINOPHEN (OTC) ACETAMINOPHEN, ASPIRIN AND CAFFEINE, ACETAMINOPHEN (OTC) ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE, ACETAMINOPHEN ACETAMINOPHEN, BUTALBITAL AND CAFFEINE, ACETAMINOPHEN ACETAMINOPHEN,...
FDA Drug Approvals List May 2001
Pylori eradication to reduce the risk of duodenal ulcer recurrence, maintenance of healed duodenal ulcers, short-term treatment of active benign gastric ulcer, short-term treatment of symptomatic gastroesophageal reflux disease (GERD), short-term treatment of erosive esophagitis, maintenance of healing of erosive esophagitis, and pathological hypersecretory conditions including...
http://www.fda.gov/cder/da/ddpa92.wpd
73 085 FLUOCINONIDE NMC FLUOCINONIDE 02 14 92 (CREAM) GLENDALE, NY 0.05% 11385 (CORTICOSTEROID) 72 651 NIFEDIPINE NOVOPHARM NIFEDIPINE 02 19 92 (CAPSULE) SCARBOROUGH 10MG ONTARIO, CANADA (CALCIUM ION INFLUX INHIBITOR) 72 652* ALBUTEROL SULFATE DEY ALBUTEROL SULFATE 02 21 92 (SOLUTION/INHALATION) NAPA, CA EQ 0.083% BASE 94558 (BRONCHODILATOR) 72 646 SILPHEN SILARX DIPHENHYDRAMINE ...
Microsoft Word - betagan.doc
June 20, 2001 BETAGAN ® (Levobunolol HCl Ophthalmic Solution) 0. 5% Page 1 of 5 : MATERIAL SAFETY DATA SHEET National Fire Protection Association (NFPA) Rating: Health: 1 Flammability: 0 Reactivity: 0 Special: 0 TELEPHONE CONTACTS: Product Technical and Medical Information: (800) 433- 8871 Transportation Emergency 24- Hour Response (CHEMTREC): (800) 424- 9300...
Microsoft Word - betagan.doc page 5
Microsoft Word - betagan.doc page 4
Microsoft Word - betagan.doc page 3
Microsoft Word - betagan.doc page 2
Microsoft Word - betagan.doc page 1
Beta-blockers for glaucoma - [Medication] - Quest Diagnostics Patient Health Library
Topic Contents - Examples - How It Works - Why It Is Used - How Well It Works - Side Effects - What To Think About - References Beta-blockers for glaucoma - [Medication] - Quest Diagnostics Patient Health Library Beta-blockers for glaucoma - [Medication] - Quest Diagnostics Patient Health Library adrenergic agent, Akbeta, beta blockers, beta blocking agent, beta-adrenergic blocking...
Beta-blockers for glaucoma - [Medication] - Quest Diagnostics Patient Health Library
Topic Contents - Examples - How It Works - Why It Is Used - How Well It Works - Side Effects - What To Think About - References Beta-blockers for glaucoma - [Medication] - Quest Diagnostics Patient Health Library Beta-blockers for glaucoma - [Medication] - Quest Diagnostics Patient Health Library adrenergic agent, Akbeta, beta blockers, beta blocking agent, beta-adrenergic blocking...
Microsoft Word - Medication_Listing.doc
(ASL- 04) framycetin/ gramicidin/ dexamethasone eye ointment, each gram: (Sofracort®) 5 mg framycetin 0.05 mg gramicidin 0.5 mg dexamethasone eye drops, each mL: 5 mg framycetin 0.05 mg gramicidin 0.5 mg dexamethasone 52: 08 Anti- Inflammatory Agents dexamethasone (Maxidex®) 0.1% eye/ ear drops fluticasone MDI (Flovent®) 125 mcg/ dose 250 mcg/ dose flumethasone ...
author: Wendy Daws
Microsoft Word - Medication_Listing.doc page 25
author: Wendy Daws
Microsoft Word - ASL - 01 Autosub List.doc
nasal spray 2 sprays each nostril bid Fosamax® 10 mg od Restricted Status (RS 19) 70 mg weekly fusidic Acid (Fucidin®) cream/ ung autosubstitution to Polysporin gliclazide (Diamicron®) 80 mg od glyburide (Diabeta®) 5 mg od ipratropium/ salbutamol MDI Combivent® Inhaler ipratropium (Atrovent®) Nebulizer Solution 0.25 mg 0.5 mg ipratropium bromide...
author: Wendy Daws
Microsoft Word - ASL - 01 Autosub List.doc page 3
author: Wendy Daws
Microsoft Word - Master_Index.doc
92 29 68: 20.08 Ipecac® 27 56: 20 ipratropium bromide nebules (Atrovent®) Restricted Status (RS- 21); Autosubstitution to ipratropium MDI (ASL 01) 6 12: 08.08 ipratropium bromide MDI (Atrovent®) 6 12: 08.08 ipratropium bromide/ salbutamol sulfate nebules (Combivent®) Restricted Status (RS- 21); Autosubstitution to Combivent® MDI (ASL 01) 6 12:...
author: Wendy Daws
Microsoft Word - Master_Index.doc page 27
author: Wendy Daws
duplicates:http://www.crha-health.ab.ca/clin/cme/ccmed/ccform/mindexl.pdf
Microsoft Word - Master_Index.doc
Continuing Care Pharmacy & Therapeutics Formulary ML- Index SECTION SUBJECT Page 27 of 58 MASTER INDEX Medication Listing Index YY MM DD Original 00 10 30 Revised 01 12 19 Revised 03 10 23 DRUG NAME PAGE CLASS Lacrilube® 25 52: 36.04 lactulose (Chronulac®, Gen- Lac®) 20, 27 40: 10,56: 13 Lamictal® 15 28: 12.92 Lamisil® topical Restricted Status (RS- 17);...
author: Wendy Daws
Reference Listed Drug Labeling Approved in May 2001
May 1 FLOMAX letter label tamsulosin HCl capsules 20-579 S-007 PREVACID letter label lansoprazole delayed-release capsules 20-406 S-038 May 2 EFFEXOR EFFEXOR XR letter label venlafaxine HCl tablets venlafaxine HCl extended-release capsules 20-151 20-699 S-018 S-016 May 3 BUSPAR letter label buspirone HCl tablets 18-731 S-045 INDERIDE LA 80/50 letter label propranolol HCl/HCTZ...
author: USERNAME
4:00 page 23
author: Christine Wildman
4:00 page 25
author: Christine Wildman
CAREWEST AUTO_SUB LIST page 4
author: gord stewart
http://www.fda.gov/cder/foi/appletter/2001/19814s11ltr.pdf page 1
author: Joanne Holmes